Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Gold has demonstrated remarkable resilience despite periodic pressure from higher bond yields, while central-bank buying, geopolitical uncertainty and concerns surrounding currencies and sovereign debt continue supporting demand for the precious metal.
• China’s move to restrict certain retail paper-gold products could further reshape investor demand, although the long-term impact on physical gold remains uncertain.
• For Lahontan Gold, a sustained gold market could provide an important backdrop as the company advances its flagship Santa Fe Mine toward a potential return to production in 2027 following a 22% increase in its mineral resource estimate.

Gold’s relationship with interest rates has long been one of the most closely watched dynamics in precious-metals markets. Because gold does not generate interest or dividends, higher real yields can increase the opportunity cost of holding the metal and, under traditional market conditions, create a headwind for prices.

Yet gold has demonstrated considerable resilience in 2026, with prices recently climbing to multi-month highs despite periods of elevated Treasury yields. The market’s strength suggests that other forces, including central-bank demand, geopolitical uncertainty, fiscal concerns and investor demand for hard assets, are increasingly influencing the precious metal’s trajectory.

Central-bank buying has become an especially important part of the story. According to the World Gold Council, central banks purchased 289 tonnes of gold during the second quarter of 2026, while China’s central bank added another 20 tonnes in July. Chinese gold ETFs also continued to see inflows during July and into August.

At the retail level, China’s gold market is also undergoing a significant shift. Several major Chinese banks have moved to end certain retail paper-gold trading products linked to the Shanghai Gold Exchange, with customers encouraged to close positions, sell or take physical delivery.

The change does not guarantee a surge in physical-gold demand, and the July transition did not immediately produce a major price shock. However, it could alter how some retail investors gain exposure to gold and potentially reinforce demand for physical bullion over time.

For gold developers and explorers, the implications of a structurally stronger precious-metals market can extend beyond the commodity price itself. Higher gold prices can improve the potential economics of deposits, increase investor attention toward development-stage projects and provide companies with greater flexibility as they advance toward production.

One company positioned within this environment is Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF), a dual-listed Canadian/U.S. mine development and exploration company advancing four gold and silver projects across the prolific Walker Lane region.

At the center of the company’s strategy is the Santa Fe Mine, a past-producing open-pit, heap-leach gold-silver operation in Mineral County, Nevada. The project benefits from existing mining and processing infrastructure and a history of production, with the company now working to advance the asset toward a potential restart.

Importantly, Lahontan’s Santa Fe story has continued to expand alongside its development efforts. The company recently announced a 22% increase in the project’s Mineral Resource Estimate, with the updated resource totaling approximately 1.195 million ounces of gold equivalent in the Indicated category and 1.190 million ounces in the Inferred category, according to the August 17 announcement. The updated estimate incorporates results from 1,275 drill holes totaling more than 136,000 meters.

The resource growth provides additional scale to a project that Lahontan is simultaneously advancing through permitting, exploration, metallurgical optimization and economic work. The company’s 2026 objectives include completing an updated Mineral Resource Estimate and Preliminary Economic Assessment while continuing mine permitting activities with the goal of commencing construction in 2027.

Exploration is also providing potential avenues for further growth. Recent drilling at Santa Fe has continued to test and expand shallow oxide gold mineralization, including results from the Calvada and other target areas. In August, Lahontan reported a 12.2-meter interval grading 1.25 g/t gold at Calvada East, adding another data point to the company’s ongoing resource expansion efforts.

Beyond Santa Fe, Lahontan is advancing the West Santa Fe project, located approximately 15 kilometers west of its flagship operation. The company is conducting additional drilling there to expand and define an oxidized gold-silver system that could potentially serve as a satellite resource to Santa Fe. Lahontan’s modeling of historical drilling has indicated the potential for a substantial near-surface mineralized system, although additional exploration is required to establish a formal resource.

The combination of a potentially supportive gold market and continued project advancement creates an interesting backdrop for Lahontan. While commodity prices remain inherently cyclical and the company’s path to production still depends on permitting, economic studies, financing and successful development, Santa Fe’s expanding resource base and existing infrastructure provide a foundation from which the company is seeking to advance the project.

If gold demand remains elevated as central banks continue accumulating the metal, investors remain concerned about fiscal and geopolitical risks, and markets continue to reassess the role of hard assets, development-stage companies with sizeable resources could attract increasing attention. For Lahontan, the opportunity is to translate the growing Santa Fe resource and ongoing development work into a potential return to production, with 2027 currently serving as a key target on that path.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

• SS Innovation’s SSi Mantra system was used in more than 50 robotic surgeries in a single day at Mohak Bariatrics and Robotics in Indore, highlighting growing clinical utilization in India.
• The milestone comes as SS Innovations reports 224 SSi Mantra systems installed across 12 countries, providing a growing installed base for future procedure and instrument revenue.
• Second-quarter 2026 installations reached 30 systems, above the 25 systems modeled by the analyst cited in the supplied report.
• Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million.
• FDA review of the SSi Mantra 510(k) application is now expected by the end of the first quarter of 2027, while European CE marking remains targeted for the end of 2026.
• The company’s progress in India gives it a major commercial base while it pursues entry into the U.S. and European surgical robotics markets.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is gaining another indication of the scale that its SSi Mantra surgical robotic system can support in India, where more than 50 robotic procedures were performed in a single day at Mohak Bariatrics and Robotics in Indore.

The milestone, announced by SS Innovations on LinkedIn, came on India’s 80th Independence Day and involved procedures conducted under the leadership of Dr. Mohit Bhandari. The event is notable less for the headline number than for what it demonstrates about the potential utilization of robotic surgery in a large healthcare market where adoption is still developing (https://ibn.fm/hUbni).

For SS Innovations, India is already the most important commercial market for the SSi Mantra. The company has spent roughly three years building an installed base there, creating a foundation from which procedure volumes and recurring sales of instruments and other consumables can grow. The latest operating figures suggest that this strategy is gaining traction.

According to an analysis by Lucid Capital Markets, SS Innovations placed 30 SSi Mantra systems during the second quarter of 2026, exceeding the analyst’s expectation of 25. Cumulative installations reached 224 systems across 12 countries, representing a substantial increase from the 194 systems reported at the end of the first quarter. First-half installations reached 56 systems, compared with 38 in the first half of 2025 (https://ibn.fm/CCO32).

The corresponding financial performance also reflected the increase in system placements. Second-quarter revenue reached $13.9 million, up 39% from a year earlier, while system sales rose 41% to $12.4 million. Gross margin was 50.9%.

More important for the longer-term economics of a surgical robotics business, utilization is increasing alongside the installed base. The company reported 2,528 robotic surgeries during the quarter, a 143% year-over-year increase. Cumulative procedures performed using SSi Mantra reached 12,272, including 637 cardiac and 222 pediatric cases.

The 50-plus procedure day in Indore therefore fits into a broader pattern: hospitals that have adopted robotic systems are beginning to use them at increasingly high volumes. That matters because surgical robotics economics do not end with the sale of the capital equipment. Once a robotic system is installed, procedures can generate recurring demand for instruments and related products. Higher utilization can therefore increase the economic value of an installed system over its lifetime.

India offers SS Innovations an unusually large market in which to establish that model. The country has a large and increasingly sophisticated private healthcare sector, while demand for advanced surgical procedures continues to expand. Robotic surgery can also address geographic disparities in access to specialist expertise, particularly as SS Innovations develops its telesurgery capabilities.

The company has already demonstrated that its platform can support procedures performed over long distances. During the second quarter and early third quarter, SS Innovations reported telesurgery demonstrations connecting surgeons and patients across thousands of miles, including a robotic cardiac procedure between Guyana and India. This was later followed by an even longer world record telesurgery between Colombia and India.

Telesurgery remains an emerging application rather than the company’s principal source of revenue. The more immediate commercial opportunity is the deployment of SSi Mantra systems and the development of procedure volumes around them. The system itself is designed as a multi-arm robotic platform, with five independently controlled robotic arms and an open-console, high-definition stereoscopic interface. Its modular architecture is intended to support multiple surgical specialties.

That breadth is important when considering the company’s positioning. Affordability is part of the proposition, particularly in markets where the capital cost of robotic systems can constrain adoption. But SS Innovations is attempting to compete on the capabilities of the platform itself rather than simply presenting SSi Mantra as a lower-cost substitute.

The next major test is international regulatory expansion. SS Innovations has submitted its SSi Mantra 510(k) application to the U.S. Food and Drug Administration and is pursuing CE marking for the European Union. The company now expects completion of the FDA review by the end of the first quarter of 2027, one quarter later than previously anticipated. The CE-marking target remains the end of 2026.

U.S. and European approvals could materially expand the addressable market for SSi Mantra. Until then, India’s installed base provides SS Innovations with an opportunity to continue building clinical experience and refining its commercial infrastructure. Training is becoming an important part of that strategy. The company has established the SS International Centre for Robotic Surgery and graduated its first robotic cardiac training class in June. A larger pool of trained surgeons can support higher utilization and potentially make future system placements easier.

The company’s financial position remains a consideration for investors. The second-quarter report cited cash of $13.6 million, excluding restricted cash, and an operating cash burn of $6.5 million during the first half of 2026. Long-term debt was reported at zero, although the company had a $14.6 million bank revolving facility.

“The Q2 results reconfirm that SSII can disrupt the surgical robotics market and create an excellent business in emerging markets while awaiting U.S./EU approval, and we reiterate BUY rating, $7 price target,” the Lucid Capital Markets report states.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance.
• The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration.
• AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells.
• VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy.
• The collaboration adds to VERAXA’s growing partnering track record, which also includes its bispecific ADC discovery alliance with OmniAb.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, have reached an early research milestone in their collaboration to develop antibody oligonucleotide conjugates (“AOCs”), providing VERAXA with an initial proof point for applying its conjugation technology outside oncology (https://ibn.fm/mgy0y).

The companies announced on August 24 that an AOC candidate generated by combining their respective technologies demonstrated greater potency in an in vitro study than the equivalent unconjugated, or “naked,” oligonucleotide. The companies are now discussing the next steps for the alliance, which is aimed at potential treatments for autoimmune and chronic immune diseases.

AOCs represent a relatively new category of antibody-guided therapeutics. The basic concept combines the targeting specificity of an antibody with an oligonucleotide payload, such as an antisense oligonucleotide or small interfering RNA. The antibody acts as the targeting component, with the objective of bringing the therapeutic nucleic acid to cells expressing the relevant target.

That approach is being investigated as a way to address some of the limitations associated with systemic delivery of oligonucleotide medicines, including cellular uptake, biodistribution and potential off-target exposure.

The Secarna collaboration therefore places VERAXA at the intersection of two technology areas without requiring the company to build an entirely new therapeutic franchise internally.

Secarna brings its OligoCreator platform and expertise in oligonucleotide discovery. VERAXA contributes its antibody engineering, conjugation and click-chemistry capabilities. The original agreement, announced in September 2025, specifically contemplated using VERAXA’s click-chemistry platform to design and generate AOCs.

VERAXA’s primary development strategy remains oncology. Its principal programs are centered on BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, a platform designed to create conditionally active antibody therapeutics through dual-target recognition. Its BiTAC technology is being applied to both T-cell engagers and antibody-drug conjugates. The company is advancing its lead BiTAC-TCE program toward IND/CTA-enabling work, while its BiTAC-ADC platform has generated initial in vitro proof-of-concept data.

The company has pursued a similar partnership model in oncology. In May 2025, VERAXA entered a co-discovery alliance with OmniAb to develop a bispecific ADC for solid tumors. OmniAb contributed antibody discovery and screening capabilities, while VERAXA provided ADC linker technology and conjugation expertise. In July, VERAXA announced that the discovery phase had been completed and that the resulting VXA-222 program had advanced into its next phase, with VERAXA taking responsibility for establishing the lead candidate and conducting subsequent validation.

That progression provides useful context for the Secarna relationship. The partnerships are directed at different therapeutic areas, but they employ a similar strategic principle: combine VERAXA’s specialized antibody and conjugation capabilities with complementary technologies from outside partners.

The company has also been building intellectual-property protection around these capabilities. In July, VERAXA reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Its patent portfolio includes technologies covering conjugation and click chemistry in addition to its BiTAC-TCE and BiTAC-ADC platforms.

VERAXA describes its click chemistry as a platform for producing efficient and stable antibody-payload conjugates, with the potential to control conjugation and generate more homogeneous products. That technology was originally developed in the context of antibody-drug conjugates, but the Secarna collaboration demonstrates why such a platform may have utility across multiple antibody-guided modalities.

“Achieving this milestone in our collaboration with Secarna in less than a year demonstrates that our conjugation technology powered by our proprietary click chemistry can be applied efficiently within partnerships beyond our company’s primary focus areas in solid tumors,” said Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA. “We look forward to continuing our collaboration with Secarna, a leading innovator in oligonucleotide-based therapeutics and unlocking the breadth of opportunities in this emerging drug class.”

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

• Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue.
• Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage.
• With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair.

Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it?

Researchers are pursuing that question through a growing range of technologies, including stem cells, 3D bioprinting, tissue-engineered scaffolds and smart biomaterials. Unlike traditional implants that primarily replace or reinforce damaged structures, many of these approaches are designed to interact with the body’s own biological processes and create an environment where healthy tissue can regenerate.

Smart biomaterials are particularly interesting because they can be engineered to do more than provide physical support. Some scaffolds and hydrogels are designed to respond to biological conditions, influence cellular behavior or gradually disappear as new tissue develops.

Recent research illustrates the potential of this approach. A research team in China, for example, has developed a coral-inspired, 3D-printed scaffold designed to support bone regeneration while influencing the immune environment surrounding an injury. The work highlights a larger shift in regenerative medicine: researchers are increasingly looking to biomaterials not simply as replacement structures, but as tools that can actively support the body’s natural healing processes.

A similar philosophy is emerging in cartilage repair, where damaged tissue presents a particularly difficult challenge. Cartilage has limited natural healing capacity, meaning that injuries can persist, cause pain and potentially contribute to progressive joint degeneration. Existing treatments can help address symptoms or stimulate repair, but restoring durable cartilage remains a significant clinical challenge.

One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for tissue repair.

Its lead product, GelrinC, is a cell-free, off-the-shelf hydrogel designed to regenerate damaged cartilage. Rather than introducing cells into the knee, GelrinC is designed to create a temporary environment that supports the body’s own regenerative processes.

The procedure is relatively straightforward. GelrinC is delivered through a syringe into the cartilage lesion and then cured in place using ultraviolet light, forming a soft, rubbery implant that conforms to the damaged area. Over time, the hydrogel gradually degrades and is resorbed, while the surrounding tissue grows into the treated area.

The approach is designed to address several challenges associated with cartilage repair while avoiding the need for an off-the-shelf cellular product. By using a cell-free hydrogel, GelrinC may offer a potentially scalable approach to treating cartilage defects while supporting the body’s own repair mechanisms.

Clinical results have provided encouraging evidence for the technology. Regentis has reported substantially greater improvement in pain scores compared with microfracture at two years, while MRI assessments have shown evidence of substantial cartilage regeneration in treated lesions.

The company is now advancing GelrinC on both U.S. and European tracks. In the United States, Regentis is conducting its pivotal Phase III SAGE study as it works toward a future Premarket Approval submission to the FDA. The company recently reported that enrollment had surpassed 50%, marking another milestone in the clinical development program.

Meanwhile, GelrinC already holds CE Mark approval in Europe, where Regentis is moving toward commercialization through surgeon training and an expanding clinical network. The company has also advanced a new manufacturing process designed to significantly improve production yield by 400%, supporting the potential scalability of the technology as commercialization progresses.

Together, these developments place GelrinC within a larger movement toward regenerative orthopedic care, one in which biomaterials are increasingly being designed not simply to replace damaged tissue, but to help the body rebuild it.

For Regentis, the opportunity is to translate that scientific approach into a commercially scalable treatment for cartilage damage. With European commercialization advancing and pivotal U.S. clinical development progressing, GelrinC is moving from regenerative medicine concept toward a potential new option for patients facing the persistent challenges of cartilage injury.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

• The demand backdrop for what Numa Numa is working to develop is well documented.
• Numa Numa is pursuing the reconstruction of Panguna as its flagship long-term project, working in partnership with the mine’s customary landowners.
• Taken together, Numa Numa’s portfolio reflects a coherent and integrated development strategy rather than a collection of unrelated bets.

The global mining industry is under real pressure to find and develop new sources of copper, gold and critical minerals as existing deposits deplete and new large-scale discoveries become harder to bring online. Numa Numa Resources is a mining and infrastructure development company that has been building its position in the Autonomous Region of Bougainville for nearly a decade, assembling a portfolio of projects that spans copper and gold exploration, industrial lime production and power infrastructure, all in a region that geologists have long identified as one of the most resource-rich in the South Pacific.

The demand backdrop for what Numa Numa is working to develop is well documented. The global copper market is facing a structural supply deficit as electric vehicle production, grid infrastructure investment and data center construction drive demand higher while the pipeline of new large-scale deposits remains thin. The International Energy Agency’s (“IEA”) Global Critical Minerals Outlook 2024 projects copper demand rising by 50% by 2040 under its Net Zero Emissions scenario, with copper demand for electricity grid lines specifically projected to more than double, driven by EV production, grid expansion and electrification across industry and transport.

Ore grades at existing mines are declining worldwide, and the average time from discovery to production for a major mining project now exceeds 16 years, a figure that has been stretching longer in recent years as permitting complexity increases globally. That combination of rising demand, falling grades and long development timelines is placing a significant premium on assets where the geology is already well understood and the ore body is already proven.

The Panguna Mine is that kind of asset. Originally developed by Rio Tinto and operating as one of the world’s largest copper and gold producers from 1972 to 1989, the mine closed prematurely and has sat dormant for more than three decades. According to Numa Numa, Panguna’s known copper reserves stand at 5.3 million metric tons, representing 5.3% of all current copper reserves globally. Known gold reserves total 547.15 metric tons, equating to nearly 1% of all global gold reserves, with value estimates of approximately $40 billion at January 2024 gold prices. During its 17 years of operation, the mine produced 3 million tonnes of copper and 9.3 million ounces of gold, leaving the remaining reserve of 5.3 million tonnes of copper and an estimated 19.3 million ounces of gold still in the ground.

Numa Numa is pursuing the reconstruction of Panguna as its flagship long-term project, working in partnership with the mine’s customary landowners. The company’s strategy for Panguna is to advance the project alongside landowner partners and then bring in major mining companies to explore, fully develop and ultimately operate the mine, with Numa Numa retaining its position as development partner and infrastructure provider throughout the process. 

Beyond Panguna, Numa Numa’s subsidiary Lakeville Mines Limited has applied for five-year exploration licenses covering the Mainoki and Karato areas, two regions that geologists have identified as among the most prospective in Bougainville and potentially comparable in scale to Panguna itself. Previous exploration work in these areas, conducted by CRA Exploration Pty. Ltd., the predecessor to Bougainville Copper Limited, identified promising mineralization that has never been fully drilled out. Numa Numa has also secured landowner agreements in both the Mainoki and Karato areas, a step the company regards as essential groundwork before formal exploration programs can begin. The company intends to partner with major mining companies for the full development of these areas in the same manner it is pursuing at Panguna.

The Manetai Limestone and Lime Project adds a near-term, operationally critical dimension to the portfolio. The project is designed to produce lime through quarrying and calcination, a process essential to the gold-copper separation that takes place in a concentrator. Numa Numa held an exploration license for the Manetai deposit and completed a prefeasibility study in December 2022; the company expects to apply to renew its exploration license to complete the Manetai project shortly. 

Lime supply is a fundamental requirement for any large-scale mining operation in the region, which means the Manetai project serves both as a standalone revenue opportunity and as a direct enabler of the broader Panguna and exploration programs. It is, as the company has described it, a key element in rebuilding the industrial foundation that mining in Bougainville depends on.

The Bougainville Power & Light Project rounds out the company’s infrastructure strategy. Numa Numa received approval from the Bougainville Department of Trade, Commerce and Industry under the Bougainville Inward Investment Act to proceed with a feasibility study for an integrated electric utility combining hydroelectric and solar generating capacity of up to 10 megawatts, and the company completed and submitted the study. The company has also received written confirmation of first preference to develop the project, subject to electricity legislation being passed. Reliable power is as foundational to modern mining as lime, roads and water, and in a region where the power grid has historically been unreliable, building that infrastructure from the ground up positions Numa Numa as an essential services provider to any future mining activity across the island.

Taken together, Numa Numa’s portfolio reflects a coherent and integrated development strategy rather than a collection of unrelated bets. The Panguna Mine reconstruction targets one of the largest proven copper and gold ore bodies in the world. The Mainoki and Karato exploration programs extend that thesis into adjacent areas with comparable geological potential. The Manetai lime project addresses one of the most fundamental industrial inputs that any Bougainville mining operation will require. And the Bougainville Power & Light project builds the energy infrastructure that makes sustained large-scale mining possible in a region that has historically lacked it. Each project reinforces the others, and together they position Numa Numa Resources as an established mining and infrastructure development company operating in one of the South Pacific’s most resource-rich environments.

For more information about the company, visit www.NumaNumaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to Numa Numa are available in the company’s newsroom at https://ibn.fm/NUM

• American Fusion is positioning its Texatron(TM) Fusion Engine(TM) for use in distributed power markets where grid constraints are becoming more significant, and has engaged national law firm Lucosky Brookman LLP to advise on a planned uplisting to Nasdaq Capital Market or other senior national exchange, including registration and SEC compliance matters.
• The global fusion sector attracted a record $4.48 billion in funding during the 12 months through July 2026, according to the Fusion Industry Association.
• Texas’ expanding artificial-intelligence and data-center economy is creating a growing requirement for reliable electricity, including power that can potentially be generated behind the meter.
• American Fusion(TM) is also evaluating hospitals, defense facilities and other critical infrastructure as potential future markets for its distributed-energy strategy.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, is putting two pieces of its long-term strategy into sharper focus: developing the Texatron(TM) Fusion Engine(TM) for potential distributed-power applications while building the corporate and capital-markets infrastructure required for a possible national exchange listing.

In an August 14 announcement, the Texas-based company provided an update on the global fusion industry, Texas’ expanding data-center market and potential applications for behind-the-meter electricity (https://ibn.fm/U0c0g). On the same day, it disclosed that it had engaged national corporate and litigation law firm Lucosky Brookman LLP as securities and capital-markets counsel for a planned uplisting.

The two developments are relevant because American Fusion(TM) is pursuing a strategy that extends beyond the eventual performance of a fusion device. The company is attempting to build a technology platform around the growing requirement for reliable electricity while simultaneously developing the regulatory and financial framework associated with a larger public company.

The broader industry backdrop has become more substantial. The Fusion Industry Association reported that 56 fusion companies raised approximately $4.48 billion during the 12 months ending in July 2026. That was the highest annual total recorded in the association’s six-year survey and brought cumulative reported fusion investment since 2021 to approximately $14.24 billion. The industry now employs more than 16,000 people.

Through its Kepler Fusion Technologies subsidiary, American Fusion(TM) is developing the Texatron(TM) Fusion Engine(TM), an aneutronic fusion platform intended for modular deployment. The company says the system is designed with potential applications in industrial, commercial, defense and other infrastructure settings. The technology remains in testing and engineering validation. Commercial applications therefore remain contingent on successful technical development, regulatory requirements, financing and manufacturing scale-up.

At the same time, American Fusion(TM) is focusing attention on a separate trend: the amount of electricity required by the expansion of artificial intelligence and data-center infrastructure. Texas has become a major destination for data-center development, but the speed of that expansion is creating challenges for the state’s power system. ERCOT has been managing a large pipeline of proposed electricity loads, while regulators and state officials have increasingly focused on ensuring that new projects can obtain power without shifting infrastructure costs or reliability risks onto existing customers.

Recent developments underscore the issue. Texas officials said in August that roughly 250 to 300 projects, most of them data centers, were subject to an ERCOT verification process. The projects represented approximately 200 gigawatts of potential future demand, more than twice the state’s previous peak demand record.

For American Fusion(TM), the significance is the potential value of electricity that can be generated closer to where it is consumed. The company believes that behind-the-meter generation could become increasingly relevant for facilities that cannot afford to wait years for transmission upgrades, substations or other grid infrastructure.

Under its proposed Power-as-a-Service model, American Fusion(TM) would ultimately seek to own, operate and maintain future Texatron(TM) generating assets and sell electricity to customers through commercial agreements.

Data centers are only one potential market for the company. Hospitals and medical centers operate around the clock and depend on electricity for critical-care systems, imaging equipment, laboratories, refrigeration, ventilation and increasingly sophisticated computing infrastructure. Defense installations, industrial facilities, mining operations and other critical infrastructure face similar requirements for dependable electricity.

“The opportunity we see developing extends well beyond any single market. Artificial intelligence is accelerating electricity demand at an extraordinary pace, but data centers are only part of the equation. Hospitals, defense installations, industrial facilities and other critical infrastructure all require reliable power,” said Brent Nelson, Executive Chairman of American Fusion(TM). “Our objective is to continue developing the Texatron(TM) into a distributed energy platform capable of ultimately delivering that power directly where it is needed.”

The second August 14 announcement addresses the other side of the company’s strategy. American Fusion(TM) has retained Lucosky Brookman LLP to advise on a planned uplisting from the OTC Markets to the Nasdaq Capital Market or another senior national securities exchange (https://ibn.fm/Jfx2I). The firm’s mandate includes preparation of a registration statement, SEC review and comment responses, an exchange listing application, periodic SEC reporting and corporate-governance matters.

American Fusion(TM) has also said it intends to evaluate the Texas Stock Exchange alongside Nasdaq. The company is headquartered in Texas, and its Texatron(TM) engineering and testing activities are being conducted in the state, creating a geographic connection to the emerging exchange.

No final listing venue has been selected, and an uplisting remains subject to satisfying applicable requirements and completing the necessary regulatory and corporate processes. 

“Our objective is to build American Fusion into a company that institutional investors can underwrite and that a national exchange can list. That requires the right technical program, the right governance, and the right advisors. This engagement is a deliberate step toward the standard we intend to operate at,” Nelson concluded.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Silynxcom is positioned within a tactical headset market where Market Research Future data projects the in-ear segment to grow at a 42% CAGR from 2021 through 2027 as military and law-enforcement users increasingly transition from conventional over-ear systems.
• The company has developed a differentiated tactical communications platform combining proprietary in-ear voice capture, Hear-Thru situational awareness, hearing protection, modular radio connectivity and newer capabilities addressing drone detection and other evolving battlefield requirements.
• Silynxcom reported approximately $7.3 million in backlog as of April 30, 2026, exceeding the company’s $5.8 million in total revenue for 2025.
• Recent military orders and deliveries in Asia and Europe demonstrate progress in Silynxcom’s strategy to expand internationally and diversify beyond Israel, which accounted for approximately 74% of 2025 revenue.
• Silynxcom’s modular product architecture, international distribution strategy and applications spanning military, law enforcement, riot control, shooting sport and industrial markets provide multiple channels for expanding adoption of its core communications and hearing-protection technologies.
• Silynxcom continues to invest in research and development to expand its product portfolio and enhance its tactical communications platform, with recent development efforts including drone detection, sound-leak testing and advanced audio functionality.

Silynxcom (NYSE American: SYNX) develops, manufactures and sells ruggedized tactical communication and hearing-protection systems designed for use in demanding environments. The company’s roots in acoustics and sound science extend back more than five decades, beginning with a family-founded music conservatory and subsequent work in hearing-aid development before that expertise was applied to tactical audio systems. Silynx Communications, a fully owned subsidiary, was incorporated in 2005, and the company has since built its business around compact, combat-proven communication solutions designed to combine hearing protection, clear communications and environmental awareness.

Silynxcom’s systems are used across military, law enforcement, shooting sport, industrial and riot-control applications, with its tactical products deployed by military and law enforcement organizations internationally. The company sells directly to military forces, police and other law enforcement units while also working through specialized local distributors and maintaining strategic relationships with radio and tactical-equipment manufacturers.

Silynxcom continues to expand internationally through direct customer relationships, formal procurement programs, distributors, agents and resellers, with recent military orders and deliveries in Asia and Europe supporting that strategy.

The company is headquartered in Netanya, Israel.

Products

CLARUS and FORTIS

Silynxcom’s CLARUS and FORTIS systems provide scalable control of tactical communications networks. CLARUS I controls one or two radios through a compact dual-PTT controller, while CLARUS II adds a third radio channel and advanced audio routing for personnel operating across multiple communications networks.

FORTIS is the company’s most advanced system, with four PTT buttons capable of controlling up to four independent radio networks. The system is designed for commanders, joint terminal attack controllers and team leaders managing more complex communications requirements.

Both product families are built around a modular architecture that allows operators to pair Silynxcom sound-protection controllers with in-ear or over-the-ear headsets, exchange radio cable adapters for different communications platforms, and add wired or wireless PTT controls and other accessories as operational requirements change.

PROTEGO

The PROTEGO family comprises Silynxcom’s in-ear tactical sound-protection headsets, led by the flagship PROTEGO PRO. The system combines advanced hearing protection, Hear-Thru ambient hearing enhancement and the company’s proprietary TRUE VOICE, or “Talking from the Ear,” technology, which captures speech from within the ear canal without requiring a conventional external boom microphone.

PROTEGO PRO is certified to a 31 dB Noise Reduction Rating (“NRR”) and is IP68 waterproof. Its external microphone is positioned within the ear canal, allowing the user’s pinna to remain uncovered to support natural directional hearing. The headset also incorporates an AUX connection supporting optional vest-mounted and helmet-mounted boom microphones and gas-mask microphones and is compatible with Silynxcom systems through the company’s Quick Disconnect Connector (“QDC”).

The broader PROTEGO family provides configurations for different operational requirements. PROTEGO STD is a standard dual-ear configuration, PROTEGO SNG provides a single-ear option for users seeking situational awareness on the unprotected side, and PROTEGO MLD offers a molded custom-fit configuration. All variants connect to Silynxcom control boxes through the QDC architecture.

Tactical Audio Technology

Silynxcom’s technology platform combines active and passive hearing protection, Hear-Thru ambient sound enhancement, TRUE VOICE in-ear voice capture and modular QDC connectivity. The company has expanded this platform with capabilities including drone detection, sound-leak testing and prerecorded messages, as well as Net Monitoring, Whisper Mode, smartphone connectivity, TacTuner software and LinkDetect technology.

Other Products and Applications

Beyond its core military systems, Silynxcom applies its communications and hearing-protection technologies across law enforcement, riot control, shooting sport and industrial environments. Applications include systems designed for use with riot helmets, gas masks and shields; in-ear electronic hearing protection for shooting, hunting and competition; and communication and hearing-protection solutions used in industrial settings including steel mills, iron-smelting facilities and nuclear power plants.

Market Opportunity

Silynxcom is targeting an active tactical sound-protection headset market that the company expects to undergo a significant transition from traditional over-ear systems toward in-ear products. According to Market Research Future data included in Silynxcom’s investor materials, the in-ear portion of the global active tactical sound-protection headset market was projected to grow at a compound annual growth rate (“CAGR”) of 42% from 2021 through 2027, compared with a projected 0.51% CAGR decline for over-ear sound-protection headsets during the same period.

The company’s materials identify several factors supporting this transition, including military and law-enforcement modernization programs focused on tactical communications and equipment miniaturization, increased awareness of hearing loss in combat and riot situations, the need for protection against louder weapons systems, and adoption of lighter radios and data devices intended to improve individual communications and situational awareness. Silynxcom also identifies industrial and commercial demand associated with workplace safety, operational efficiency, coordination, noise reduction, training and hands-free operation.

Additional opportunities include increased European military and homeland-security modernization funding, the transition by Asian military forces from over-ear to in-ear communications devices, increased mobile-device usage by law enforcement agencies and a growing proportion of procurement requirements specifying in-ear rather than over-ear sound protection. The company is pursuing these opportunities through direct sales, formal purchasing programs, an international distributor network and strategic relationships with established equipment manufacturers.

Leadership Team

Nir Klein, Chief Executive Officer and Director, has served as Silynxcom’s CEO since January 2011 and as a member of its board of directors since August 2021. He holds a B.A. in accounting and economics from Tel Aviv University and brings extensive operational experience through his leadership of the company.

Ilan Akselrod, Chief Financial Officer, has served as Silynxcom’s CFO since September 2014. Before assuming his current role, he served as a controller at Mobile Technologies Ltd. from June 2010 through August 2014. Akselrod holds a B.A. in economics and accounting and a master’s degree in economics from Bar Ilan University.

Gal Nir Klein, Vice President of Marketing and Israel Sales and Director, has served as Silynxcom’s Vice President of Marketing and Israel Sales since October 2005 and as a member of its board of directors since August 2021. She holds a B.A. in economics from Tel Aviv University.

Elihay Cohen, Vice President of Marketing and International Sales Officer, has served in his current position since July 2021 after working as a consultant to Silynxcom during the first half of that year. He previously served as vice president of marketing and international sales for a large tactical-gear producer and has 20 years of prior management and sales experience in the high-tech sector. Cohen holds a B.Sc. in industrial engineering from Tel Aviv University.

Ronen Hananis, Vice President of Operations and Development, has served in his current role since July 2017 and has held various positions with Silynxcom since October 2005. He previously served as R&D and Engineering Manager from February 2014 through October 2016 and, prior to that, as Engineering Manager. Hananis holds a B.Sc. in electronics from the Holon Institute of Technology.

For more information, visit the Silynx website at https://silynxcom.com.

NOTE TO INVESTORS: The latest news and updates relating to SYNX are available in the company’s newsroom at https://ibn.fm/SYNX

• Silynx, producer of field-tested, certified, and combat-proven in-ear tactical communication headset systems, offers clear communication and situational awareness, along with hearing protection, to clients across multiple sectors including military, law enforcement, sport shooting, industrial, and riot control.
• The company’s tactical headsets are built on proprietary technologies that offer a blend of protection, communication, and comfort for operators who don’t compromise on effectiveness, comfort, and overall quality.
• Full tactical communication systems offer Silynx Drone Detection providing the ability to better hear and act upon distant drone activity
• Silynx world sales continue to expand, including a recent $3 million order of advanced tactical communication solutions in Asia, and selection as a final bidder for two major U.S. DOD programs.

Whether you’re on the battlefield, in a tense SWAT operation, or working in a loud factory, hearing protection that keeps you safe, but doesn’t hurt your ability to hear your surroundings and communicate with others, is crucial to your success and comfort. Without an effective solution, you can miss critical commands, warnings, or other vital information, or can permanently damage your hearing.

Silynxcom (NYSE American: SYNX) has the mission of creating certified and field-tested in-ear communication headsets that not only offer hearing protection, but also ensure consistent communication and situational awareness.

The company develops, designs, and manufactures rugged tactical and commercial communication headsets, currently selling them to hundreds of customers across more than 40 countries, for military, law enforcement, shooting sport, industrial, and riot control application. Importantly, Silynx works directly with end users for valuable feedback to continually drive design decisions and improvements. As a result, the company has customers that have provided recurring orders for years. There’s a rapidly-growing market for superior quality tactical in-ear headsets, versus traditional over-ear designs, and Silynx is creating a first-mover advantage in the space.

Silynx’s tactical communication headsets are built on three proprietary technologies and certification standards:

• First, the TRUE VOICE in-ear microphone captures voice from inside the ear canal with “Talking from the Ear” microphone technology, eliminating the need for boom mics or throat mics, while reducing wind noise.
• Next, there’s the HearThru electronic ambient pass-through technology, which offers situational awareness by picking up environmental sounds through external mics, and playing it back through the in-ear speakers at an adjustable volume.
• For certifications, there is MIL-STD-810, covering environmental/ruggedness testing (temperature, shock, humidity, immersion).  In addition, it provides an NRR (Noise Reduction Rating) in accordance with ANSI S3.19, achieving one of the highest ratings in the in-ear tactical hearing protection category.

Silynx headsets are also waterproof (with an IP68 rating, tested for immersion), as well as being incredibly light, at under 5 grams per earbud. They are also small enough to easily fit under helmets, riot visors, gas masks, and ballistic eyewear, and feature wide compatibility with radio, intercom systems, and smartphones. 

Silynx offers a full scope of products and accessories to fit a range of needs, including in-ear sound protection headsets, sound protection radio controllers, single-side headsets, over-the-ear sound protection headsets, active sound protection plugs, wired and wireless push-to-talk (“PTT”), and more. 

The company also provides entire tactical communication systems, combining rugged and waterproof command units, in-ear headsets, and a variety of cables and adapters. These systems also come with Silynx Drone Detection, an industry-first capability, which is an audio enhancement mode designed to help hear distant drone activity quicker and more clearly.

Silynx continues to expand sales operations and activities in numerous regions, including Asia and Central Europe, fulfilling a growing list of orders, including a recent $3 million order of advanced tactical communication solutions to a prominent military customer in Asia (https://ibn.fm/44UPO).

In addition, the company has partnered with leading international manufacturers, engaging with emergency services and first responder agencies. 

For more information, visit the Silynx website at https://silynxcom.com.

NOTE TO INVESTORS: The latest news and updates relating to SYNX are available in the company’s newsroom at https://ibn.fm/SYNX

• India’s medical-device market is projected to grow from $15.2 billion in 2025 to $50.1 billion by 2030, with the possible 26.9% CAGR creating a significant domestic and export opportunity for Indian medical-device manufacturers.
• SS Innovations is already commercializing the SSi Mantra surgical robotic system from its Indian base, having installed 224 SSi Mantra systems across 12 countries by June 30, providing an established platform as India expands its MedTech manufacturing ambitions.
• For SSII, India’s push to reduce medical-device import dependence could create opportunities extending beyond domestic sales into manufacturing, exports, and international technology adoption.
• The company is actively seeking both US FDA clearance and European Union CE mark certification to expand its flagship SSi Mantra surgical robotic system globally.

India’s next major manufacturing opportunity may emerge not from information technology or semiconductors, but from medical devices. An observation from business developer Shaad Merchant, quoting a recent report from Rubix Industry Insights, shows India’s medical-device market projected to increase from $15.2 billion in 2025 to $50.1 billion by 2030, representing a compound annual growth rate of 26.9%. That projected expansion would place medical devices among India’s faster-growing industrial and healthcare segments (https://ibn.fm/19Onj).

The timing is particularly relevant for SS Innovations International (NASDAQ: SSII), which is developing and commercializing surgical robotic technology from India while expanding the international footprint of its SSi Mantra system.

The opportunity is not limited to market consumption. India is also seeking to increase its domestic manufacturing capacity and reduce dependence on imported medical technology. The Rubix report said medical-device exports reached $4.1 billion in fiscal 2025, while imports were approximately $8.6 billion, and estimated that 70% to 80% of domestic medical-device demand is still met through imports, particularly for technologically advanced products.

India currently ranks as the fourth-largest medical-device market in Asia and among the world’s top 20, according to the Rubix report. The government has introduced several initiatives intended to strengthen the domestic ecosystem, including the National Medical Devices Policy, Production Linked Incentive Scheme, the Scheme for Promotion of Medical Devices Parks and MedTech Mitra. The broader policy objective is to increase India’s share of the global medical-device market from approximately 1.6% toward 12% over the coming years.

Unlike some areas of healthcare, sophisticated medical equipment can also create industrial capabilities that extend across multiple markets. Manufacturing robotic surgical systems, for example, requires expertise in precision engineering, software, electronics, imaging, instrumentation and systems integration.

SS Innovations is already building that type of capability around its SSi Mantra platform. The company is not simply participating in India’s medical-device market as a distributor of imported equipment. Its SSi Mantra is a proprietary surgical robotic system developed for use across multiple specialties, including cardiac surgery.

The opportunity becomes more relevant when viewed alongside SSII’s recent financial performance. The company reported second-quarter 2026 revenue of $13.9 million, an increase of 39.4% from $10.0 million in the second quarter of 2025. Gross profit increased 20% to $7.1 million. For the first six months of 2026, revenue reached $25.0 million, up 65.6% from $15.1 million in the comparable period. Gross profit increased 77.5% to $12.4 million, while first-half gross margin improved to 49.6%.

System installations provide another measure of the company’s progress. SS Innovations installed 30 SSi Mantra systems during the second quarter, compared with 23 a year earlier. First-half installations reached 56, versus 38 during the first half of 2025. By June 30, the cumulative installed base had reached 224 systems across 12 countries. Those systems had been used in 12,272 surgeries, including 175 telesurgeries, 637 cardiac procedures and 222 pediatric procedures. That installed base gives SSII an important starting point as India develops its medical-device manufacturing ecosystem.

The SSi Mantra is a modular surgical robotic system with three to five robotic arms, an ergonomic surgeon command center and a 3D 4K display. Its instrument portfolio is designed to support multiple surgical specialties.

SSII has also continued to develop telesurgery capabilities. In April, the company hosted the Global Multi-Specialty Robotic Surgery Conference in New Delhi, attracting more than 1,600 attendees in person and 1,800 virtual participants from 19 countries, according to the company.

In May, surgeons completed a telesurgery between Australia and India using the SSi Mantra. In June, the company announced a robotic-assisted cardiac procedure conducted between Guyana and India across approximately 12,500 miles of fiber-network distance. After the second quarter ended, SSII announced another long-distance telesurgery. On July 29, surgeons led by CEO Dr. Sudhir Srivastava performed a robotic sleeve gastrectomy between Colombia and India across more than 13,600 miles of fiber-network distance.

Ultimately, India’s medical-device expansion may help companies such as SS Innovations build scale beyond the domestic market. The United States and Germany are already among India’s key medical-device export destinations, while the U.S. and China are major sources of imports, according to the Rubix report.

For SSII, that creates a potential two-stage opportunity. The first is to deepen its position in India as the country expands access to advanced medical technology. The second is to use India’s manufacturing and engineering base as a platform for international expansion, especially in underserved countries and aiming for entry into the United States and European Union, according to recent comments by Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations. 

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation.
• Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations.
• First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT.
• Nanox has secured FDA clearance for Nanox.ARC, Nanox.ARC X and three Nanox.AI medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s Hospital.

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

Technology and Services

Nanox.ARC

Nanox.ARC is an FDA-cleared and CE-marked stationary digital multi-source tomosynthesis system that produces three-dimensional radiographic images while reducing the superimposition of anatomical structures. The company offers the system through a capital-purchase model or a pay-per-scan medical screening-as-a-service (“MSaaS”) model that does not require an upfront capital expenditure.

Nanox.ARC X is the company’s next-generation, FDA-cleared system, combining a compact 15-by-10-foot space requirement and standard 110-volt power connection with the ability to generate up to 200 coronal images per scan. According to Nanox, the system delivers approximately 80% less radiation than a CT scan, can be billed under CPT code 76100 and is designed to receive future capabilities remotely following applicable regulatory clearance.

A Nanox.ARC system was also in commercial use and integrated into routine clinical workflow at a RadNet facility.

Nanox.AI

Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI, Nanox.AI helps clinicians extract valuable and actionable clinical insights from medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. Nanox states that its AI technology draws on 30 million patient records, 10 years of patient history and 500 million images across multiple imaging modalities. In one reported deployment, Corewell Health used the cardiac solution to identify nearly 4,000 new patients with coronary artery calcification in 2023, compared with 268 patients whose calcification had been reported during the preceding two years.

In July 2026, Nanox announced that data from studies involving Brigham and Women’s Hospital, Massachusetts General Hospital, the University of Texas Southwestern Medical Center and other institutions would be presented at the Society of Cardiovascular Computed Tomography’s annual scientific meeting. The studies evaluated HealthCCSng’s agreement with expert assessment and whether AI-detected coronary calcium could help clinicians identify opportunities for preventive lipid-lowering therapy.

Nanox.CLOUD

Nanox.CLOUD supports image processing, radiology services and Nanox.ARC fleet management through capabilities including cloud-based image reconstruction, centralized protocol management, continuous updates and remote support. The platform can be hosted locally or in the cloud and is designed for HIPAA and GDPR compliance.

Other Technology and Services

The remainder of the Nanox ecosystem includes USARAD’s teleradiology services, Nanox.MARKETPLACE’s web-based connection of imaging facilities with diagnostic expertise, and Nanox Health IT’s healthcare IT solutions, including RIS, PACS, AI, dictation and secure infrastructure offerings.

Nanox also offers its proprietary cold-cathode X-ray source and tube technology, a core component of the company’s imaging platform, to original equipment manufacturers through hardware, licensing and royalty arrangements for potential medical, industrial and security applications.

Leadership Team

Erez Meltzer, Chief Executive Officer and Acting Chairman of the Board, leads Nanox after previously serving for six years as chairman of Hadassah Medical Center in Israel. His career also includes leadership roles at Gadot Chemicals & Shipping Group, Africa Israel, Netafim and Creo Scitex.

Guy Nathanzon, Chief Financial Officer, has held senior CFO and COO positions at U.S. publicly traded companies and medical technology businesses, with experience supporting commercialization, organizational growth and global operations. He previously served as CFO of AI-based medical diagnostics company Scopio Labs and most recently served as CFO of New York Stock Exchange-listed Valens Semiconductor.

For more information, visit the company’s website at www.Nanox.vision.

NOTE TO INVESTORS: The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX